These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18981781)

  • 1. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
    Poveda E; de Mendoza C; Pattery T; González Mdel M; Villacian J; Soriano V
    AIDS; 2008 Nov; 22(17):2395-8. PubMed ID: 18981781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
    Scott C; Grover D; Nelson M
    AIDS; 2008 May; 22(8):989-90. PubMed ID: 18453859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
    Vingerhoets J; Tambuyzer L; Azijn H; Hoogstoel A; Nijs S; Peeters M; de Béthune MP; De Smedt G; Woodfall B; Picchio G
    AIDS; 2010 Feb; 24(4):503-14. PubMed ID: 20051805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database.
    Poveda E; Anta L; Blanco JL; Pérez-Elías MJ; García F; Leal M; Ribera E; Gutiérrez F; Soriano V; de Mendoza C;
    AIDS; 2010 Jan; 24(3):469-71. PubMed ID: 20057310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
    Cotte L; Trabaud MA; Tardy JC; Brochier C; Gilibert RP; Miailhes P; Trépo C; André P
    J Med Virol; 2009 Apr; 81(4):672-7. PubMed ID: 19235860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J;
    HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Fulco PP; McNicholl IR
    Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
    Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
    HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
    Vingerhoets J; Nijs S; Tambuyzer L; Hoogstoel A; Anderson D; Picchio G
    Antivir Ther; 2012; 17(8):1571-9. PubMed ID: 22869341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etravirine: genetic barrier and resistance development].
    Llibre JM; Santos JR; Clotet B
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():32-9. PubMed ID: 20116626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).
    Di Vincenzo P; Rusconi S; Adorni F; Vitiello P; Maggiolo F; Francisci D; Di Biagio A; Monno L; Antinori A; Boeri E; Punzi G; Perno CF; Callegaro A; Bruzzone B; Zazzi M;
    HIV Med; 2010 Sep; 11(8):530-4. PubMed ID: 20236364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short communication prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV type 1 resistance testing in the United States.
    Picchio G; Vingerhoets J; Tambuyzer L; Coakley E; Haddad M; Witek J
    AIDS Res Hum Retroviruses; 2011 Dec; 27(12):1271-5. PubMed ID: 21557669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.
    Neogi U; Shet A; Shamsundar R; Ekstrand ML
    AIDS; 2011 May; 25(8):1123-6. PubMed ID: 21505320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
    Marcelin AG; Flandre P; Descamps D; Morand-Joubert L; Charpentier C; Izopet J; Trabaud MA; Saoudin H; Delaugerre C; Tamalet C; Cottalorda J; Bouvier-Alias M; Bettinger D; Dos Santos G; Ruffault A; Alloui C; Henquell C; Rogez S; Barin F; Signori-Schmuck A; Vallet S; Masquelier B; Calvez V;
    Antimicrob Agents Chemother; 2010 Jan; 54(1):72-7. PubMed ID: 19901096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.
    Poveda E; Garrido C; de Mendoza C; Corral A; Cobo J; González-Lahoz J; Soriano V
    J Antimicrob Chemother; 2007 Dec; 60(6):1409-10. PubMed ID: 17913723
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
    AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.
    Kagan RM; Sista P; Pattery T; Bacheler L; Schwab DA
    AIDS; 2009 Jul; 23(12):1602-5. PubMed ID: 19474648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.